Analysis of time-dependent alterations of parameters related to erythrocytes after ipragliflozin initiation
- 10 November 2020
- journal article
- research article
- Published by Springer Nature in Diabetology International
- Vol. 12 (2) , 197-206
Abstract
Sodium-glucose cotransporter 2 (SGLT2) inhibitors often increase the hematocrit. It remains unclear whether this increase would be observed in all patients administered SGLT2 inhibitors, however. We therefore used the data from the previous study and investigated time-dependent alterations of various outcomes related to erythrocytes, erythropoiesis, and clinical outcome in type 2 diabetes subjects (n = 89) treated with ipragliflozin for 16 weeks. Among a total of 89 participants, 71 subjects (80.0% of total participants) showed the elevation of the hematocrit and 18 subjects (20.0% of total participants) did not at 16 weeks. Although the hematocrit levels at baseline were significantly lower in hematocrit-elevated group than non-elevated group, they reached the same levels 4 weeks after the onset of treatment. Binomial logistic regression analysis demonstrated that a lower baseline hematocrit level was related to the elevation of hematocrit at 16 weeks. Optimal cutoff hematocrit levels at baseline to predict hematocrit elevation were 46.9% (male) and 41.7% (female) in ROC analysis. Random intercept model analysis revealed the serum erythropoietin level increased in both hematocrit-elevated and non-elevated groups, whereas only the former group showed an increase in the percentage of reticulocytes during the first 4 weeks. These results suggest that the ipragliflozin-induced increase in hematocrit which is affected by the baseline hematocrit level is attributable to the responsiveness to, but not to the production of, erythropoietin. Collectively, Ht elevation observed in administration of SGLT2 inhibitors can result from erythropoietin-induced erythropoiesis, which is determined by the pre-treatment Ht level. Trial registration: This trial has been registered with University Hospital Medical Information Network Clinical Trial Registry (UMIN-CTR no. 000015478).Keywords
Funding Information
- Astellas Pharma (1)
This publication has 23 references indexed in Scilit:
- Diuretic effects of sodium–glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failureInternational Journal of Cardiology, 2015
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Renal erythropoietin-producing cells in health and diseaseFrontiers in Physiology, 2015
- Effect of the sodium glucose co‐transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitusDiabetes, Obesity and Metabolism, 2014
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes MellitusCirculation, 2014
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patientsJournal of Clinical Investigation, 2014
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose productionJournal of Clinical Investigation, 2014
- Randomized, placebo‐controlled, double‐blind glycemic control trial of novel sodium‐dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitusJournal of Diabetes Investigation, 2013
- Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetesDiabetes, Obesity and Metabolism, 2013
- Improved glycemic control in mice lacking Sglt1 and Sglt2American Journal of Physiology-Endocrinology and Metabolism, 2013